Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00621946 · ClinicalTrials.gov registry record · Phase 4
Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder
A Phase 4 study of Severe Asthma and Moderate or Severe Major Depressive Disorder, sponsored by University of Texas Southwestern Medical Center.
- Completed
- Registry status
- Phase 4
- Development phase
- 26
- Enrollment target
- 1
- Study location
NCT00621946: Completed Phase 4 study of Severe Asthma and Moderate or Severe Major Depressive Disorder, sponsored by University of Texas Southwestern Medical Center.
NCT00621946 is a Phase 4 study of Severe Asthma and Moderate or Severe Major Depressive Disorder that has completed, run by University of Texas Southwestern Medical Center. The registered enrollment target is 26 participants, below the 3,852-participant average among 9 other Severe Asthma trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00621946, a Phase 4 study of Severe Asthma and Moderate or Severe Major Depressive Disorder, has completed, sponsored by University of Texas Southwestern Medical Center.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 26 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma symptoms than placebo in outpatients with severe asthma and moderate or severe MDD. 3) Escitalopram treatment will be associated with greater depressive symptom remission rates than placebo in outpatients with severe asthma and moderate or severe MDD.
Primary Outcome
The HAM-D is a 17 item questionnaire (a clinician-administered depression scale) designed to evaluate severity of depressive symptoms. Scores can range from 0 to 52. The higher the score, the worse the depressive symptoms (worse outcome).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Escitalopram
Study Locations (1)
Texas
- The UT Southwestern Medical Center at Dallas - Dallas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2008-03 |
| Est. Completion | 2010-03 |
| Phase | Phase 4 |
What the finished NCT00621946 record still lists
NCT00621946 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 26 participants, a relatively small participant target, below the 3,852-participant average among 9 other Severe Asthma trials with a reported enrollment target (99% lower).
The record links to 2 conditions, with Severe Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT00621946 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT00621946 about?
NCT00621946 is a clinical study titled "Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder". The purpose is to determine if: 1) Escitalopram treatment will be associated with less oral corticosteroid use than placebo in outpatients with severe asthma and moderate or severe major depressive disorder (MDD). 2) Escitalopram treatment will be associated with greater improvement in asthma sympto...
What is the current status of trial NCT00621946?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 26 participants. The study started on 2008-03. Estimated completion is 2010-03.
What conditions does trial NCT00621946 study?
This clinical trial studies the following conditions: Severe Asthma, Moderate or Severe Major Depressive Disorder.
What interventions are being tested in trial NCT00621946?
The interventions under investigation include: Placebo (DRUG), Escitalopram (DRUG).
Who is sponsoring clinical trial NCT00621946?
This trial is sponsored by University of Texas Southwestern Medical Center, which has 837 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00621946 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Severe Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00621946's enrollment target sits among peer trials
26 8th of 9 higher than 2 of 9 other Severe Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Severe Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Downstream Effects of Airway Mucus Plugs on 129Xenon MRI in Severe Asthma
RECRUITING
-
A Long-Term Safety and Efficacy Study of Verekitug (UPB-101) in Adult Participants With Severe Asthma (VALOUR)
RECRUITING · Phase 2
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-2)
RECRUITING · Phase 3
-
Phenotyping Asthma for Bronchial Thermoplasty
RECRUITING
-
Evaluation of Ventilation Defects Downstream of Mucus Plugs in Patients With Severe Asthma
RECRUITING
-
A Study to Investigate GB-0895 Adjunctive Therapy in Adults and Adolescents With Severe Uncontrolled Asthma (SOLAIRIA-1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02646475 · 26 participants · Phase 1
Metabolic Effects of Angiotensin-(1-7)
- NCT03603223 · 26 participants · Phase 2
Pembrolizumab in Treating Participants With Leukoplakia
- NCT04063592 · 26 participants · NA
AMI Construction in Lower Extremity Residual Limbs
- NCT04906460 · 26 participants · Phase 1
Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia